Business Description
Aclaris Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US00461U1051
Total Employee Number:
73Compare
Compare
Traded in other countries / regions
ACRS.USA0H8T.UK8AT.Germany Index Membership
Russell 2000Russell 3000Russell 2000Russell 3000 IPO Date
2015-10-07Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.72 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.04 | |||||
Beneish M-Score | -4.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -48 | |||||
3-Year EBITDA Growth Rate | 22.6 | |||||
3-Year EPS without NRI Growth Rate | 25.9 | |||||
3-Year FCF Growth Rate | 28.3 | |||||
3-Year Book Growth Rate | -33.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -13.74 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -8.77 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.64 | |||||
9-Day RSI | 68.19 | |||||
14-Day RSI | 62.94 | |||||
3-1 Month Momentum % | 28.13 | |||||
6-1 Month Momentum % | 48.84 | |||||
12-1 Month Momentum % | 189.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.03 | |||||
Quick Ratio | 4.03 | |||||
Cash Ratio | 3.85 | |||||
Days Sales Outstanding | 74.51 | |||||
Days Payable | 504.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.8 | |||||
Shareholder Yield % | -8.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 9.69 | |||||
Operating Margin % | -938.01 | |||||
Net Margin % | -832.58 | |||||
EBITDA Margin % | -932.89 | |||||
FCF Margin % | -614.95 | |||||
OCF Margin % | -623.94 | |||||
ROE % | -54.2 | |||||
ROA % | -37.78 | |||||
ROIC % | -85.01 | |||||
3-Year ROIIC % | 24.67 | |||||
ROC (Joel Greenblatt) % | -9496.97 | |||||
ROCE % | -49.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 74.63 | |||||
PB Ratio | 4.86 | |||||
Price-to-Tangible-Book | 4.85 | |||||
EV-to-EBIT | -7.55 | |||||
EV-to-EBITDA | -7.6 | |||||
EV-to-Revenue | 70.86 | |||||
EV-to-Forward-Revenue | 76.3 | |||||
EV-to-FCF | -11.52 | |||||
Price-to-GF-Value | 11.11 | |||||
| Price-to-Net-Current-Asset-Value | 12.82 | |||||
| Price-to-Net-Cash | 13.89 | |||||
Earnings Yield (Greenblatt) % | -13.25 | |||||
FCF Yield % | -7.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Aclaris Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.367 | ||
| EPS (TTM) ($) | -0.56 | ||
| Beta | 1.0854 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 0.67 | ||
| Volatility % | 51.28 | ||
| 14-Day RSI | 62.94 | ||
| 14-Day ATR ($) | 0.269042 | ||
| 20-Day SMA ($) | 4.527 | ||
| 12-1 Month Momentum % | 189.1 | ||
| 52-Week Range ($) | 1.3801 - 5.15 | ||
| Shares Outstanding (Mil) | 139.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aclaris Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aclaris Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 39 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 14:00 | 4.42 (-4.54%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 4.42 (-4.54%) | ||
| Guidance call for 2026 | 2026-05-14 09:35 | 5.09 (+5.38%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.78 (-0.62%) | ||
| Aclaris Clinical Program Update | 2026-04-28 08:30 | 4.41 (+2.56%) | ||
| H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference | 2026-04-14 12:00 | 3.90 (-3.47%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 13:40 | 3.39 (+13.38%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 08:40 | 3.31 (-2.07%) |
Show
Entries
Aclaris Therapeutics Inc Frequently Asked Questions
What is Aclaris Therapeutics Inc(ACRS)'s stock price today?
The current price of ACRS is $5.00. The 52 week high of ACRS is $5.15 and 52 week low is $1.38.
When is next earnings date of Aclaris Therapeutics Inc(ACRS)?
The next earnings date of Aclaris Therapeutics Inc(ACRS) is 2026-08-07 Est..
Does Aclaris Therapeutics Inc(ACRS) pay dividends? If so, how much?
Aclaris Therapeutics Inc(ACRS) does not pay dividend.
Guru Commentaries on NAS:ACRS
No articles.
Press Release
Articles on Aclaris Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers